John Heinrich
Dr. Heinrich’s decision to resign
Highest-materiality recent filing
Sensus Healthcare enters into $15M revolving credit facility with City National Bank of Florida
$15M revolving credit facility; initial $2M available secured by $2.23M cash collateral and blanket asset lien.
Sensus Healthcare shareholders re-elect directors, approve advisory vote on pay, ratify auditor
Eric Sachetta and Michael J. Sardano re-elected as Class II directors for three-year terms.
Sensus Healthcare Q1 revenue drops to $3.4M; cash $18.3M, no debt
Revenue of $3.4M, down 59% vs $8.3M in Q1 2025; no sales to historically largest customer (15 units in prior year).
Sensus Healthcare Q4 2025 revenue $4.9M, net loss $3.2M; CMS code boost effective Jan 2026
Q4 revenue $4.9M, down from $13.1M YoY; net loss $3.2M ($0.19/sh) vs net income $1.5M ($0.09/sh) in Q4 2024.
Sensus Healthcare dismisses BPB, appoints CRI as auditor after asset acquisition
Audit committee simultaneously dismissed BPB and approved CRI as independent auditor on Jan 13, 2026.
Sensus Healthcare appoints Larry Biscotti to Board of Directors
Larry Biscotti appointed as Class I director effective January 5, 2026, term expiring at 2028 annual meeting.
Sensus Healthcare appoints Eric Sachetta to board of directors
Eric Sachetta, 37, fills vacancy from death of Director William McCall.
Sensus Q3 2025: Revenue down 21.6% to $6.9M; net loss of $0.9M vs profit of $1.2M a year ago
Net loss of $0.9M ($0.06 per share) vs net income of $1.2M ($0.07 diluted) in Q3 2024.
Revenue $7.3M vs $9.2M YoY; net loss $1.0M ($0.06/sh) vs net income $1.6M ($0.10/sh) in Q2 2024.
Anthony Petrelli re-elected as Class I director for three-year term; votes: 4,325,657 for, 1,563,543 against, 13,305 abstentions.
Revenue $8.3M, down 22% YoY from $10.7M; net loss $0.16 per share vs. net income $0.14 per diluted share.
Sensus Healthcare resumes $3M share repurchase program, citing compelling opportunity
Resumes purchases under $3.0M buyback program approved August 2023; 9,427 shares already repurchased.
Sensus Healthcare Q4 revenue $13.1M, EPS $0.09; record 39 SRT shipments; Q1 sales expected lower
Q4 2024 revenue $13.1M (+4% YoY); full-year revenue $41.8M (+71% YoY).
Sensus Q3 revenues double to $8.8M; net income $1.2M vs loss; targets >50 IG-SRT deals by year-end
Revenue $8.8M (+127% YoY); net income $1.2M ($0.07 diluted EPS) vs net loss $1.5M ($0.09 loss) in Q3 2023.
Sensus Healthcare Q3 2024 revenue doubles to $8.8M; net income of $0.07 per diluted share
Revenue $8.8M (+127% YoY); net income $1.2M vs net loss $1.5M in Q3 2023.
Marcum resigns as Sensus auditor over merger conflict; BPB appointed
Marcum resigned Sept 5, 2024, effective immediately, due to independence concerns from its merger with CBIZ Inc., which provides HR/insurance services to Sensus.
Sensus Healthcare Q2 2024 revenue $9.2M (+104% YoY); net income $1.6M
Revenue $9.2M vs $4.5M in Q2 2023, up 104%; 23 systems shipped (including 3 to Asia) vs 13 last year.
Megan Cornish and Joseph Sardano elected as Class III directors for three-year term ending 2027.
Sensus Healthcare director Dr. John Heinrich resigns from board effective immediately
Dr. John Heinrich resigned from Sensus Healthcare's Board of Directors on May 30, 2024, effective immediately.
Sensus Healthcare Q1 revenue $10.7M (up 214% YoY); net income $2.3M vs loss of $1.9M
Revenue $10.7M, up 214% from $3.4M; shipped 26 systems vs 10 YoY.
Dr. Heinrich’s decision to resign
Max materiality 0.85 · Median 0.65 · Most common event earnings